
Asst Prof UConn and Quinnipiac Univ, #PatientCare #HospitalMedicine #PrimaryCare, Indian Air Force (Ex-Major)
Hartford, CT
Joined October 2021
- Tweets588
- Following613
- Followers269
- Likes1.3K
Where purpose and clarity of vision are forged together by bringing disparate groups together to achieve a greater good @ConnecticutACP. Come join and grow together.
The professional home of #IMphysician #IMproud @ACPIMPhysicians.
Varun Jain, MD FACP retweeted
Sarcopenia is more than a disease of muscle. This new review reframes it as a disorder of the aging motor system, integrating neural drive, neuromuscular function, muscle quality, strength, and physical performance. An interesting perspective on how we assess and treat muscle health with aging. #Sarcopenia
thelancet.com/journals/lanhl…
This is going to be a wonderful drug. But the cost at this time seems prohibitive for adoption for a lot of patients. Will have to see how we navigate that.
First pill that blocks PCSK9 approved by FDA, achieves LDL cholesterol lowering comparable to injectables (Repatha, Praluent) nytimes.com/2026/07/16/scien…
Varun Jain, MD FACP retweeted
A new issue of Annals of Internal Medicine is online now. Read the latest at bit.ly/4rhjz7F
Varun Jain, MD FACP retweeted
I love @satyanadella his ability to put technology transformations in simple terms is par none. In this instance I think it's important to understand the distinction in consumer, horizontal multi-tenant AIaaS and Enterprise which tends to be deep and vertical.
1. Consumer - this is not new news, the consumer has always been part of the product. Be it search (Bing or Google), social media (think TikTok, Snap, and of course FB), even unassuming products like Maps have always retained the knowledge learnt from customers, customers suspecting or unsuspecting have always had the choice. Use the product and share your prompts, location or preferences and that will be used to build a better product. So why is that surprising if it happens in AI, the model complex will continue to use consumer usage to train fundamental multiple modalities. This is the biggest technological event of our lifetime :).
2. Horizontal AIaaS (AI capability that doesn't need to be too enterprise specific - can be tuned, but is a 80% common use case) - Think coding, legal, many current SaaS categories - most likely agentic development for prosumers. All of this behavior is being used to train the model complex to get better at all these. The large swath of small medium size businesses will be fertile training grounds for such applications. They cannot deal with isolated apps and custom deployments.
3. Enterprise deployments - this is where I am not sure the reverse information paradox applies. There is an existing model of isolated single tenant public cloud deployments, deployments where our data, code and connectivity are both isolated and in the hands of the enterprise. This is the deployment we have for our development from all frontier models. All our grounding data, prompts, internal tribal knowledge is sequestered. This is important because this is where enterprise IP will reside. It will be a large task to capture, collate, interpret this data. Equally complex to maintain, evolve and make effective an enterprise AI architecture. But that is what we all will need to sign up for.
This is not a cloud vs on prem debate, they can both be equally secured. On prem is probably more unwieldy at the moment given the fast pace of development.
Varun Jain, MD FACP retweeted
Another new report confirms small excess risk of GLP-1 drugs for NAION, a vision-threatening condition (acronym for nonarteritic anterior ischemic optic neuropathy)
acpjournals.org/doi/epdf/10.…
Eye opening…. Need to watch out now we interact with AI as physicians.
For medical information, general AI frontier models (Google, OpenAI, Anthropic) outperformed specialized @openevidence and @UpToDate as assessed by 12 US clinicians, randomized and blinded to which model and extensive testing/benchmarks. This was not anticipated. @NatureMedicine
nature.com/articles/s41591-0…
Varun Jain, MD FACP retweeted
🧵The 2026 ACC/AHA Dyslipidemia Guidelines are officially out!
These new updates bring major shifts in risk assessment, novel lipid markers, and cholesterol targets.
Open access 🔓
jacc.org/doi/pdf/10.1016/j.j…
Here are the most salient features you need to know.👇
Varun Jain, MD FACP retweeted
New ACC/AHA Guidelines published today for lipids
address measuring Lp(a) and ApoB
jacc.org/doi/10.1016/j.jacc.…
Is it time to start de-prescribing?
Meta-analysis of four randomized trials found β-blockers did not reduce mortality, recurrent #MyocardialInfarction (MI), heart failure, or revascularization in patients with preserved left ventricular ejection fraction after MI. ja.ma/3Nv7DQn
Varun Jain, MD FACP retweeted
Meta-analysis of four randomized trials found β-blockers did not reduce mortality, recurrent #MyocardialInfarction (MI), heart failure, or revascularization in patients with preserved left ventricular ejection fraction after MI. ja.ma/3Nv7DQn
Varun Jain, MD FACP retweeted
Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial academic.oup.com/eurheartj/a…
Varun Jain, MD FACP retweeted
The harmful and biased medical advice from social medial influencers, highlighting lack of expertise, and financial conflicts. Many specific examples and recommendations provided @bmj_latest
bmj.com/content/391/bmj-2025…
Varun Jain, MD FACP retweeted
Today, @WHO published a guideline in JAMA on the use and indications of #GLP1 therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for the global treatment of #obesity in adults. ja.ma/48CbXFB 🧵
Varun Jain, MD FACP retweeted
Over the past two decades, the risk of stroke in atrial fibrillation patients decreased significantly among all age groups, with no subsequent increase in the risk of bleeding.
Read more in #EHJ
@escardio @ESC_Journals #atrialfibrillation
academic.oup.com/eurheartj/a…
Varun Jain, MD FACP retweeted
Cellular and molecular imaging of coronary atherosclerosis: clinical applications. A State-of-the-Art review just published in #EHJ 👉 ow.ly/OihU50Xtky7
@RoccoMontone @ehj_ed
Varun Jain, MD FACP retweeted
In older patients with myocardial infarction and multivessel disease, physiology-guided complete revascularization achieved a sustained reduction in adverse outcomes compared to culprit-only treatment over a 3-year follow-up period. ja.ma/49VzS3N


































